Megatrials for Bronchodilators in Chronic Obstructive Pulmonary Disease (COPD) Treatment: Time to Reflect by Dijk, W.D. van et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/118792
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
RESEARCH LETTER
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Time to Reflect
Wouter D. van Dijk, MD, Lisette van den Bemt, PhD, and Chris van Weel, MD, PhD
Introduction: Chronic obstructive pulmonary disease (COPD) is an important cause of morbidity and
mortality worldwide. Although (long-acting) bronchodilators are used to relieve symptoms, the impact
of bronchodilators on COPD mortality remains an unresolved issue. Our aim was to explore the results
and the interpretations of the results of studies of bronchodilator treatment from high-impact COPD
trials.
Methods: We searched PubMed and Embase for primary publications of randomized controlled trials
with more than 1000 participants with COPD and that studied the effectiveness of long-acting broncho-
dilator treatment. We assessed population characteristics, primary outcomes, focus of outcomes, and
possible bias from concomitant pulmonary medication.
Results: We retrieved 5 primary publications of large trials. Participants tended to be patients with
rather severe COPD who were cared for at a hospital. Only half of the primary outcomes were statisti-
cally significant. Reports tended to focus on statically significant outcomes and not necessarily on pri-
mary outcomes or outcomes of the whole study population. The relevance of study outcomes was rarely
discussed.
Discussion: The rather small effects of bronchodilators in a COPD population that is not representa-
tive for daily care, together with the tendency of relying on statistical rather than clinical significance,
hampers translation to the large number of patients with COPD in the community. (J Am Board Fam
Med 2013;26:221–224.)
Keywords: Bronchodilators, Chronic Disease, Chronic Obstructive Pulmonary Disease (COPD), Pharmacotherapy,
Respiratory Tract Diseases
Chronic obstructive pulmonary disease (COPD) is a
progressive chronic disease characterized by not fully
reversible airﬂow obstruction. It is one of the most
important causes of morbidity and mortality world-
wide, directly related to cigarette smoking. Indeed,
cessation of cigarette smoking is the single-most efﬁ-
cient intervention to prevent both disease develop-
ment and progression.1,2 In addition, (long-acting)
bronchodilators are used to relieve symptoms. An
unresolved question is the impact of bronchodilators
on COPD mortality, in part by attenuation of pul-
monary function decline and exacerbations, indepen-
dent from desired symptom relief. The last decade, a
number of large studies on the effectiveness of long-
acting bronchodilators received extensive attention in
leadingmedical journals. Calverley observed that “en-
suring that these expensive studies are done objec-
tively to the highest standard is an important goal”.3
For that reason, the quality of these large trials, their
external validity, and what they add to the current
clinical practice, are of importance.We systematically
reviewed the results and the interpretations of these
results of megatrials on long-acting bronchodilators
in COPD patients that were published in high impact
journals.
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Methods
WD and LB conducted a search in both PubMed
and Embase until 2011, July 31st, containing
(Mesh) terms of COPD and bronchodilators. We
included primary publications in leading journals
with an impact factor 15 in 2011 of randomized
controlled trials with more than 1000 participants
with COPD, that studied the effectiveness of long-
acting bronchodilator treatment. WD and LB in-
dependently and systematically assessed population
characteristics, primary outcomes, focus of out-
comes, and possible bias from concomitant pulmo-
nary medication.
Results
We retrieved ﬁve primary publications of large
trials on bronchodilator effect in COPD patients,
including 1465 to 7376 patients with a mean fol-
low-up between 6 and 48 months (Table 1).4–8
Mean COPD severity as measured by percentage of
predicted forced expiratory volumes ranged from
36% to 49% at baseline. The mean proportion of
males was 77%. All studies included patients with
at least 10 pack-years smoking history only, and
patients with co-prevalence of asthma were ex-
cluded. Certain types of pulmonary co-medication
were allowed during all studies, but none of the
analyses were adjusted for these co-medications
during follow-up. Table 1 also summarizes the var-
ious effects of bronchodilators on primary out-
comes. Primary outcomes were mortality,6 exacerba-
tions5,8 and lung function decline.4,7 Although all studies
report positive outcomes for the study medication of
interest in general, only three of six primary outcomes of
the studies were statistically signiﬁcant.4,5,8 Clinical sig-
niﬁcance was discussed in two trials only.4,5 The statis-
tically signiﬁcant primary outcomes include pre-
bronchodilator FEV1 change (post-bronchodilator
FEV1 was not statistically signiﬁcant in this study),
4
percentage of patients with exacerbations (the other pri-
mary outcome: number of hospitalizations for exacerba-
tions, did not statistically differ signiﬁcantly between
groups),5 and time to exacerbations (a statistically
signiﬁcant modiﬁed population of analyses).8 Stud-
ies focused on statistically signiﬁcant secondary
outcomes,4,7 and statistically signiﬁcant subgroup
analyses.7 Although two studies acknowledged sta-
tistically non-signiﬁcant results for the primary
outcome they focused on its beneﬁcial effect,6,7 and
on the secondary outcome.6 One study did notTa
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always correctly stated the population key charac-
teristics,8 whereas another used pre-bronchodilator
values as primary outcome.4
Discussion
Despite the positive tone in the reports of large
trials on long-acting bronchodilator therapy in
COPD patients, only half of the primary outcomes
were statistically signiﬁcant. Next, reports tend to
focus on statically signiﬁcant outcomes and not
necessarily on primary outcomes or outcomes of
the whole study population.
Compared with combining results of smaller
rigorous trials into meta-analyses, megatrials could
provide a small advantage on minimizing con-
founding by change.9 However, since large trials
increase their participant numbers by reducing pro-
tocol rigidness, bias can be introduced that weakens
causative interpretations.10 For instance, in these
COPD megatrials, various co-medications were al-
lowed during the study without proper adjustments
for it in the analyses. On the other hand, decreased
rigidness may provide a generalization of results in
daily practice, but only if the study population is
representative of the target population to which its
results will be applied.9 Moreover, the clinical rel-
evance of the rather small effects in a possibly
biased COPD population that is not representative
for daily care should be debated, in particular as
meta-analyses rate these trials on their patient
numbers mostly.
Most patients with COPD are treated in the
community, while the selection of patients for large
trials is biased toward referred, hospital cared pa-
tients. This, together with the tendency of relying
on statistical rather than clinical signiﬁcance, ham-
pers translation to the large number of patients
with COPD in the community. Independent from
symptom relief, we would therefore plea for some
precaution on the customary prescription of long-
acting bronchodilators for the COPD population
at large.
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